Background: Inflammatory bowel disease (IBD) is a chronic, relapsing inflammatory disorder of the gastrointestinal tract that includes two entities, namely Crohn's disease (CD) and ulcerative colitis (UC). Objective: The aim of the study was to identify the inflammatory bowel disease and significance of the drugs therapy in treatment with behavior of disease. Method: This study was conducted on 100 patients with inflammatory bowel disease attending Tripoli Medical Center during the period from June 2019 to June 2020. Information was taken from patient files. Statistical analysis was computerized using the Statistical Program for Social Sciences (SPSS version 21) that used for data entry and analysis. A P-value of less than or equal to 0.05 was considered statistically significant. Result: Regarding the age distribution in this study, the study result revealed that most of the cases were ranged from 20-40 years followed by 41-60 years age group. According to classification of the disease locations, this study classified the disease into four locations as follow: L1 (Terminal ileum) in 29% of cases. L2 (Colon) was found in 19% of cases. L3 (Ileocolon) was the predominant in 43% of cases. L4 (Upper GI) was the less frequency in 9% of cases. The result reported many drugs have been taken by patients, and most of the drugs were taken mixed with other drugs, the common drug was AZA in almost 60% of cases, prednisolone and Mesalamine were existed in about 50% of cases.
Amer et al. (Tue,) studied this question.